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Abstract
Background: Ebola virus disease (EVD) is an often-fatal infection where the effectiveness of medical countermeasures
is uncertain. During the West African outbreak (2013–2016), several patients were treated with different types of anti-
viral therapies including monoclonal antibody-based cocktails that had the potential to neutralise Ebola virus (EBOV).
However, at the time, the efficacy of these therapies was uncertain. Given the scale of the outbreak, several clinical
phenotypes came to the forefront including the ability of the same virus to cause recrudescence in the same patient—
perhaps through persisting in immune privileged sites. Several key questions remained including establishing if
monoclonal antibody therapy was effective in humans with severe EVD, whether virus escape mutants were selected
during treatment, and what is the potential mechanism(s) of persistence. This was made possible through longitudinal
samples taken from a UK patient with EVD.
Methods: Several different sample types, plasma and cerebrospinal fluid, were collected and sequenced using
Illumina-based RNAseq. Sequence reads were mapped both to EBOV and the human genome and differential gene
expression analysis used to identify changes in the abundance of gene transcripts as infection progressed. Digital Cell
Quantitation analysis was used to predict the immune phenotype in samples derived from blood.
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Results: The findings were compared to equivalent data from West African patients. The study found that both virus
and host markers were predictive of a fatal outcome. This suggested that the extensive supportive care, and most likely
the application of the medical countermeasure ZMab (a monoclonal antibody cocktail), contributed to survival of the
UK patient. The switch from progression to a ‘fatal’ outcome to a ‘survival’ outcome could be seen in both the viral and
host markers. The UK patient also suffered a recrudescence infection 10months after the initial infection. Analysis of
the sequencing data indicated that the virus entered a period of reduced or minimal replication, rather than other
potential mechanisms of persistence—such as defective interfering genomes.
Conclusions: The data showed that comprehensive supportive care and the application of medical countermeasures
are worth pursuing despite an initial unfavourable prognosis.
Background
Ebola virus disease (EVD) has a high case fatality rate and
is caused by infection of humans with Ebola virus (EBOV)
[1]. Once confined to isolated outbreaks, West Africa wit-
nessed the largest ever EBOV outbreak between 2013 and
2016 [2] and a large outbreak then occurred in the Demo-
cratic Republic of Congo [3]. The outcome of infection
(death/survival) in EVD may be influenced by several fac-
tors including viral load [4, 5], the host response [6, 7] and
the presence of other infections at the time of acute symp-
toms [8]. Generally, at the time of diagnosis, for the West
African outbreak, patients with higher viral loads (as mea-
sured by RT-qPCR) had a poorer prognosis than patients
with lower viral loads [5]. RNA sequencing of blood sam-
ples taken by the European Mobile Laboratory (EMLab)
from acute patients at the time of presentation to a treat-
ment centre during the West African outbreak indicated
that the blood transcriptome was different between indi-
viduals in the acute phase who went on to have a fatal in-
fection or survived [6, 7]. This included stronger
upregulation of interferon signalling and acute phase re-
sponses in patients progressing to a fatal infection and in-
creased NK-cell populations in patients who went on to
survive infection. During the West African outbreak, sev-
eral medical countermeasures were used and evaluated
both in Africa and on repatriated health care works in-
cluding favipiravir, convalescent plasma and monoclonal
antibodies targeted against the EBOV glycoprotein (GP)
[9–11]. Whilst the presence of EBOV in seminal fluid was
described in 1977 [12] and shown to persist after non-
detectable amounts were found in the blood [12], the
West African outbreak illustrated that a number of pa-
tients had recrudescent infections. This often correlated
with persistence of the virus in what can be described as
immune-privileged sites including the testes [13] and the
eye [14]. Analysis of EBOV evolution rates in semen sug-
gested a mechanism of persistence rather than latency and
indicated that EBOV replication continued during conva-
lescence [15].
Thus, several key questions remained including establish-
ing if monoclonal antibody therapy was effective in humans
with severe EVD, whether virus escape mutants were se-
lected during treatment, and what is the potential mecha-
nism(s) of persistence. Such a study was made possible in a
healthcare worker in the UK with EVD (referred to as UK2),
who had recently returned from Sierra Leone and who devel-
oped relapse of EVD in association with meningoencephalitis
10months after initial presentation [16]. Longitudinal and re-
crudescence blood, plasma, and cerebral spinal fluid samples
were taken from UK2; RNA was extracted and sequenced.
This provided a unique opportunity to study both EBOV
population genetics and the host response over the course of
EVD and to probe the effectiveness of antibody-based inter-
ventions given as part of extensive supportive care. The peak
viral load in UK2 during the early course of infection and to-
gether with host markers was predictive of a fatal outcome
when compared to equivalent Guinean patients. Our study
found little change in overall EBOV consensus sequence, or
at a minor variant level despite the application of selection
pressure (in the form of antibody-mediated therapy) or be-
tween initial infection and recrudescence 10months later,
suggesting a phase of reduced or low level replication, with
concomitant undetectable viral load. Changes in the blood
transcriptome during EBOV infection in UK2 demonstrated
that many of the markers for inflammation and the innate
response were much more abundant than that of patients in
West Africa, at a similar time point in infection, who went
on to have a fatal infection and far greater than those who
survived in this setting. This study provides molecular data
to support the observation that the extensive care given to
UK2 tipped the balance to survival [17]. The unusual situ-
ation of a patient recovering from an infection associated
with very high viral load (that without high level critical care
would almost certainly have resulted in death) could also
prove useful for comparison with fatal EBOV challenge ex-




Samples were collected as part of diagnostic testing
process and retained for research purposes with patient
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consent. Samples were tested in accordance with con-
sent and ethical approval. All blood specimens collected
for RT-qPCR in this study were collected into EDTA
blood collection tubes. CSF was collected directly into
plastic tubes without buffer. Blood and CSF was proc-
essed for RNA extraction immediately on arrival into the
diagnostic testing laboratory and residual RNA used in
this analysis.
RT-qPCR analysis of viral RNA
For extraction and purification of viral RNA, the
QiaAMP Viral RNA Mini Kit (Qiagen) was used. This
kit was validated as a suitable method for extraction of
viruses by diagnostic clinical laboratories, and the ability
of the contained Buffer AVL to neutralise Ebola virus
has supporting evidence in the literature [18]. Initial
samples prior to confirmed diagnosis of EVD were han-
dled at ACDP (Advisory Committee for Dangerous
Pathogens) Containment Level 3. Subsequent specimens
were handled in ACDP Containment Level 4 facilities.
Inactivation was performed by addition of 140 μl plasma
into 560 μl Buffer AVL; after 10 min incubation at room
temperature, 1:1 volume of 100% molecular grade Etha-
nol was added (Sigma-Aldrich) and incubated for a fur-
ther 10 min. After inactivation specimens were surface
disinfected by 10% sodium hypochlorite and transferred
to Containment Level 2 for extraction and purification.
Viral RNA was quantified using the Nanodrop 2000
(Thermo Scientific) or Qubit (ABi; Thermo Scientific).
The standard Nanodrop 2000 assay for RNA concentra-
tion estimation was performed and ratios at 260/280 nm
and 260/230 nm calculated to ascertain purity. Samples
below an expected value of 1.8 were retested and, if per-
sistently below this level, were re-extracted; no samples
used in this project failed this basic quality check. For
concentration estimation by Qubit assay, the Broad
Range RNA kit (ABi; Thermo Scientific) was used. A
synthetic control was designed using sequence from the
region targeted by the RT-qPCR assay used in this pro-
ject to use as control template [19]. This synthetic oligo-
nucleotide sequence was cloned into the pMX-01 vector
under the control of a T7 promoter (GENEArt; Thermo
Scientific) and sequence verified by Sanger sequencing
at GENEArt (Thermo Scientific) and Public Health Eng-
land’s Sequencing Service, Colindale, London, UK.
Quantitative real-time reverse transcription polymerase
chain reaction (RT-qPCR) was used to quantify the
abundance of viral genome in study materials. Rather
than designing a new assay, an assay with established ef-
fectiveness and with validation data supporting usage
was selected. This assay has been validated for clinical
diagnostic use in the Rare & Imported Pathogens La-
boratory, part of Public Health England, UK, and utilised
in examining samples from patients with EVD [19].
The RT-qPCR primers were designed as described for
EBOV targeting the glycoprotein (GP) gene sequence,
including MGB probe design (Thermo Scientific). For-
ward primer (900 nM), 900 nM Reverse primer and 250
nM Probe were added to each reaction. Sequences of the
primers and probe were Forward: 5′-TTT TCA ATC
CTC AAC CGT AAG GC-3′, Reverse: 5′-CAG TCC
GGT CCC AGA ATG TG-3′, and Probe: 6FAM-CAT
GTG CCG CCC CAT CGC TGC-BHQ-3′. The Taq-
MAN Fast Virus kit was used for reverse transcription
and PCR (Thermo Scientific), and water used in the re-
action was nuclease free water (Qiagen).
Sequencing and bioinformatics analysis
Samples from the patient from the initial infection or re-
crudescence were either sequenced on MiSeq or HiSeq
platforms as described previously [8, 16, 20]. Briefly,
RNA extraction from plasma and CSF was carried out in
Containment Level 3 on the easyMag platform according
to the manufacturer’s instructions, or on further samples
from the initial infection by PHE at Containment Level
4. CSF eluate was treated with RNase-free DNase I
(Ambion), purified with RNAClean XP magnetic beads
(Beckman Coulter) and eluted into 11 μl of water.
Plasma eluate was concentrated using magnetic beads as
indicated above, in the absence of DNase I treatment.
Samples were reverse transcribed using Superscript III
(Invitrogen) followed by dsDNA synthesis with NEB
Next(r) mRNA Second Strand Synthesis Module (NEB).
Libraries were prepared using a KAPA DNA Library
Preparation Kit (KAPA Biosystems), following a modi-
fied protocol as previously described. Resulting libraries
were quantified using a Qubit 3.0 fluorometer (Invitro-
gen) and their size determined using a 2200 TapeStation
(Agilent). Libraries were pooled in equimolar concentra-
tions and sequenced on the MiSeq and NextSeq Illumina
platforms.
In this analysis, a human genome assembly GRCh38
with its gene structures (release-91) from Ensembl and
an EBOV genome (GenBank sequence accession:
KY426690) were used as references. Tophat2 v2.1.1 [21]
was used to map RNAseq reads to the human reference
and Cufflinks v2.2.1 [22] to determine normalised hu-
man gene expression levels (FPKM). Hisat2 v2.1.0 [23]
was used to map the trimmed reads on the human refer-
ence genome assembly with default setting.
FPKM calculated using Cufflinks was used as input
data into Digital Cell Quantitation, which uses transcrip-
tomic patterns to infer the predicted activity of immune
cell types. The unmapped reads were extracted by bam2-
fastq (v1.1.0) and then mapped on the EBOV reference
genome using Bowtie2 v2.3.5.1 [23] by setting the option
to parameters “--local”, followed by Sam file to Bam file
conversion, sorting, and removal of the reads with a
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mapping quality score below 11 using SAMtools v1.9
[24]. After that, the PCR and optical duplicate reads in
the bam files were discarded using the MarkDuplicates
in the Picard toolkit v2.18.25 (http://broadinstitute.
github.io/picard/) with the option of “REMOVE_DUPLI-
CATES=true”. The resultant Bam file was processed by
Quasirecomb v1.2 [25] to generate a phred-weighted
table of nucleotide frequencies which were parsed with a
custom perl script to generate a consensus genome se-
quence as our previous description [4]. The consensus
genome was then used as a template in the second
round of mapping to generate the final consensus gen-
ome sequences and corresponding phred-weighted table
of nucleotide frequencies. yn00 in the PAML package in
the R environment was utilised to calculate rate of nu-
cleotide substitution within the patient and compare this
with published rate of substitution determined through
analysis of multiple patients across transmission events.
Consensus genome sequences (Supplementary data 1)
and a phred-weighted table of nucleotide frequencies
(Supplementary data 1) were obtained for each sample.
These nucleotide frequencies were used for comparison
of minor variation. These consensus genome sequences
were aligned with Mafft v 7.402 [26]. The aligned ge-
nomes were partitioned into four sets of sites: 1st, 2nd
and 3rd codon positions of the protein-coding regions
and the noncoding intergenic regions. PartitionFinder
v2.1.1 [27] was then used to find the best-fit substitution
model and distribution of rates for each set. Four Bayes-
ian nucleotide divergence tree for these sets was then
constructed using MrBayes v3.2.6 [28], a Bayesian ana-
lysis tool with their best-fit substitution model and
distribution of rates. The final consensus genome se-
quences were also used as reference to identify DI events
by running the DI-tector v0.6 [29] programme with de-
fault setting.
Results
Studies describing EVD over the course of an infection
in humans under controlled conditions are rare. Gener-
ally, these have made use of laboratory accidents [12] or
healthcare and related workers who were given extensive
supportive care, and treated with experimental medical
countermeasures [30]. Currently, none of the medical
countermeasures for Ebola virus are of absolute proven
benefit, although some hold promise [10, 11]. The ana-
lysis of longitudinal samples provides greater insight into
EVD, and where given, the potential role of medical
countermeasures in facilitating survival.
Overview of UK2 upon presentation with and during EVD
In December 2014, a healthcare worker returned to the
UK from West Africa with acute febrile illness. On pres-
entation at hospital (referred to as day 1), the patient
had a markedly elevated temperature of 39.3 °C and was
haemodynamically unstable but responded rapidly to
rapid intravenous fluids and antibiotic therapy. RT-
qPCR for EBOV genome was performed by the Royal In-
firmary of Edinburgh Clinical Virology Department in
conjunction with the Rare & Imported Pathogens La-
boratory (days 1–2) and Virus Reference Department,
Colindale (days 3–28) (part of PHE). The patient’s initial
sample tested positive for EBOV RNA, and the patient
was transferred to the high-level isolation unit at the
Royal Free Hospital, London, UK, on the 2nd day after
admission (referred to in this study as day 2). To ensure
consistency, all samples used in this study were retested
and EBOV quantified using the Trombley RT-qPCR
assay that targets a region within the GP coding
sequence.
A Ct value of 23.9 in the GP gene qRT-PCR assay was
recorded at presentation (day 1). On day 2, this changed
to Ct 21.2 in the GP gene assay. The patient was treated
with one oral dose of Brincidofovir (200 mg) (an experi-
mental antiviral drug) and two doses of convalescent
plasma (300 ml) on consecutive days, obtained from a
survivor of EVD. By day 5, symptoms worsened, and the
patient developed severe watery diarrhoea and type 1 re-
spiratory failure. The patient also developed erythro-
derma, mucositis and agitation, but did not develop
overtly haemorrhagic manifestations.
The highest viral load was recorded on day 6 (Ct 14.3),
and the severity of the patient’s illness approximately
correlated with viral load. The viral load data from this
patient was compared with diagnostic findings from
European Mobile Laboratory in the 2013–2016 West Af-
rican outbreak [5]. West African patients in the outbreak
with Ct of ~ 14, and treated in West Africa, all had a
fatal outcome. This illustrated the severity of illness for
UK2, and on this basis, the patient would have been pre-
dicted not to survive EVD.
The patient was administered ZMAb (50 mg/kg) by in-
fusion on day 5 and day 8. After day 12 of the illness,
the viral load began to decrease. By day 21, the patient
had developed a pronounced thrombocytosis (peaking at
1726 × 109/L; normal range 150–400) and was dis-
charged on low-molecular-weight aspirin and heparin
[31] following two consecutive negative RT-qPCR fur-
ther on days 25 and 28 of illness, in accordance with
general WHO advice. The overall course of illness was
very similar to the clinical findings of outbreaks caused
by other variants of EBOV. However, 10 months follow-
ing this illness, the patient was readmitted with a previ-
ously undescribed presentation of relapse of EVD in
association with the presence of virus in both plasma
and cerebral spinal fluid (CSF) [16].
To investigate virus evolution and the host response to
EBOV over the course of the primary infection and
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during recrudescence, longitudinal analysis using RNA-
seq was carried out using available samples and com-
pared to equivalent patients from West Africa (Table 1).
These included a plasma sample sequenced upon initial
admission (day 1), blood samples taken over the acute
phase between days 4 and 12, and during recrudescence,
a plasma and CSF samples. These latter samples were
from the same lumbar puncture, but separate aliquots
sent to independent laboratories who received them on
different days. Sequence reads were mapped to the
EBOV genome and the human genome (Table 1). The
sequence read depth across the EBOV genome was ap-
proximately equivalent for the different samples suggest-
ing that viral genomic RNA had been sequenced rather
than EBOV mRNA (Fig. 1), which would have been as-
sociated with a higher proportion of reads mapping to
the genes located towards the 3′ end of the negative
strand genome [32].
Analysis of viral genome abundance by RNA-seq in UK2
with time post-admission suggested a viral load
associated with a fatal outcome at the early stages of
infection
The sequencing data from the blood samples (Table 1)
also provided an independent comparison of the relative
amount of EBOV between each day post admission
using the number of sequence reads mapped to the viral
genome and clarified ambiguity with the RT-qPCR-
based assays. Analysis of diagnostic leftover plasma/
blood samples taken from patients during the West Afri-
can outbreak in Guinea showed a close correlation at ad-
mission between viral load as determined by RT-qPCR,
Table 1 Sequencing reads across patient timeline for UK2 and also comparative data from selected EMLab patients (IDs 413, 753,
578, 462 and 351).
Plasma Blood
Day 1 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12
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Fig. 1 Time-course showing viral load as measured by RT-qPCR of the GP gene of EBOV in samples collected from a UK case of EVD. The X-axis
displays the days post symptoms. The right-hand y-axis displays the relative viral genome abundance (calculated by PCR maximum cT (30) −
sample cT to calculate the proportional inverse value). The left-hand y-axis displays RNAseq data from the blood samples as reads mapping to
the EBOV genome as a proportion of total reads. The peak of viremia is discernible at day 6
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genome abundance determined by the number of
mapped reads and outcome (survival/death) [4]. There-
fore, for each sequenced sample for UK2, the proportion
of reads mapping to the EBOV genome was compared
to the total number of reads (Table 1). This value was
then compared to the viral load data—derived from RT-
qPCR analysis of blood samples (Fig. 1). This compari-
son revealed that where data for both viral load and
reads mapping to the EBOV genome were available,
there was a close correlation between both measure-
ments. Both viral load and percentage reads mapping to
the EBOV genome peaked on day 6. The percentage of
reads mapping to the EBOV genome illustrated a sharp
increase in EBOV over a 2-day period from day 4
(1.43%) to day 6 (55.01%). After the infusion of ZMAb
on day 5, the reads mapping to the viral genome
dropped between day 6 and day 7. However, not until
days 11/12 did the percentage of reads mapping to the
EBOV genome decrease below the day 4 value. Also, for
day 6, most sequence reads mapped to the EBOV gen-
ome (Table 1).
Analysis of RNAseq data between UK2 and gender
matched data from similar blood samples from adult
Guinean patients with EVD at the time of admission
(Table 1) allowed comparative quantification of viral
loads. The samples from Guinea were taken on average
6 days post symptom onset and therefore are approxi-
mately equivalent to UK2 at the early stage of infection.
Patient 413 (Table 1) had the largest proportion of se-
quence reads mapping to EBOV, yet this was less than
UK2 at day 6. This provided further evidence for the se-
verity of this EBOV infection in the UK2 patient, and
based on this, the prediction of a fatal outcome in UK2.
Measurement of host biomarkers in UK2 and comparison
to acutely ill Guinean patients were indicative of a fatal
outcome
Analysis of the blood transcriptome in patients with
EVD can provide detailed information on the host re-
sponse to EBOV infection [6, 7]. The RNAseq data pro-
vided a readout on what host RNAs increased and
decreased in abundance in patients with EVD compared
Fig. 2 Transcript abundance data (FPKM) displayed for 16 genes characterised as known interferon stimulated genes (ISG). The transcript abundance
for each of the genes correlates well with abundances of viral RNA and they decrease over time. Transcript FPKM is shown on the y-axis for each gene
and x-axis displays the days with symptoms from day 4 to day 12. The identifier for each gene is given above each chart. A zero value indicates that
the transcripts was either not detected or the transcript was absent
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to patients without EVD. These changes in abundance
may have been caused by differential gene expression
and/or an influx or efflux of different cell types from the
blood. In this study, we made use of the sequencing data
to map reads to the human genome (Table 1). For six of
the samples, from day 7 to day 12, the number of reads
that could be mapped to the human genome was around
60%. For the other days, a lower number of reads
mapped to the human genome, reflecting the very high
viral load in UK2, and dominance of EBOV RNA in the
blood transcriptome. The abundance of transcripts was
inspected across the time course to ensure that no major
variation in either library preparation on sequencing run
introduced bias. In many cases, the abundance of tran-
scripts in the day 4 samples was higher than any of the
other samples; therefore, the dataset from this day was
treated with caution. Values from this day are included
for completeness in the analysis of differential gene ex-
pression but should not be considered definitive.
The blood transcriptome of patients in Guinea at pres-
entation to an Ebola virus treatment centre indicated in-
creased levels of interferon stimulated genes (ISGs)
relative to normal or convalescent controls [6]. Therefore,
the abundance of ISGs in UK2 was analysed. Transcripts
which were consistently detected across the longitudinal
time course were identified using the Interferome v2.01
database. In the dataset, 31 potential ISGs were identified
at all 9 time points (days 4–12). Transcripts encoding
well-characterised interferon stimulated genes are shown
in Fig. 2. FPKM values for each transcript were compared
at each time point and displayed without further process-
ing. With the general exception of the day 4 sample, the
majority of gene transcript abundance peaked with max-
imum viral genome abundance in the samples from day 5/
day 6. Reflecting data from non-human primate studies
[33] and from the blood transcriptome analysis of samples
from patients from Guinea [6], this suggested that the in-
nate response was a critical aspect of the cellular response
to EBOV.
The abundance of several host transcripts/proteins has
been shown to correlate with outcome in West African
patients with EVD. For example, fatal EVD has been as-
sociated with the increase in abundance of cytotoxic T
lymphocyte-associated protein 4 (CTLA-4) and eomeso-
dermin (Eomes), suggestive of defects in T cell homeo-
stasis [34]. Where detected by sequencing, both
transcripts were elevated in abundance at day 6 com-
pared to the other days. The abundance of chemokine
transcripts that could be detected, except for CXCL11
(which peaked on day 6), tended to peak on day 7. These
included CXCL2, CXCL9 and CXCL12 (Fig. 3) and func-
tion to recruit T cells.
Fig. 3 Transcript abundance data (FPKM) displayed for 6 genes characterised as involved in the immune response. The transcript abundance for
each gene correlates well with abundances of viral RNA and they decrease overtime. Transcript FPKM is shown on the y-axis for each gene, and
x-axis displays the days with symptoms from day 4 to day 12. The identifier for each gene is given above each chart. A zero value indicates that
the transcripts was either not detected or the transcript was absent
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Overall, the data suggested that the IFN response was
robust and to be expected in an overwhelming infection.
There was no evidence of any rare immunodeficiency in
innate immunity. Indeed comparison of day 6 levels to
equivalent Guinean patients with a fatal outcome [6]
would suggest that the innate response was generally
higher than when compared to those patients who went
on to survive EVD.
Changes in the immune cell phenotype occur as infection
progresses and viral load decreases
Potential changes in the blood/plasma transcriptome can
be through either changes in gene regulation such as dif-
ferential expression and/or through the influx and efflux
of different cell types—such as those of the immune
system. Conventionally flow cytometry is used to assess
these—however, this was not possible with samples from
this patient. Therefore, to investigate changes in the im-
mune cell phenotype, digital cell quantification (DCQ)
[35] was used to predict which cell types may have been
present at each time point by comparing the transcrip-
tomic data to a characterised healthy control group [6].
Previously, we used this approach to interrogate simi-
lar transcriptomic data from West African patients
[6]. In patients with EVD who went on to have a fatal
outcome, DCQ analysis predicted that lower levels of
circulating CD14+ classic monocytes would be
present, which was confirmed with flow cytometry
[6]. DCQ was applied to the transcriptomic data from
UK2 (Fig. 4) and indicated potential changes in the
Fig. 4 Predicted differential abundance of cell types present in the samples from UK2 at the days indicated. These are shown as relative abundance as
predicted by DCQ compared to a healthy control group at each day. Within the heatmap, darker green represents a decrease in the abundance of a
given cell type and darker red indicates an increase in the abundance of a specific cell type
Bosworth et al. Genome Medicine            (2021) 13:5 Page 8 of 18
abundance of a given cell type. Of note were the pre-
dicted increase in abundance of both natural killer
cells (CD56− CD16+ CD3−) and natural killer T cells
(NKT) cells, through alignment of the transcriptomic
profile of these cell types by the DCQ process.
Analysis of the viral genome population suggested that
escape mutants to ZMab during infection and treatment
were not selected or present
UK2 was administered ZMAb at day 5 and day 8. The spe-
cific targets of ZMab are known and found in GP. Both 2G4
and 4G7 target the base of GP, between them encompassing
amino acids C511, N550, D552, G553 and C556. Monoclo-
nal antibody 1H3 targets the glycan cap and encompasses
amino acids W275, K276 and P279. To investigate whether
there were any changes in GP (or other EBOV proteins),
EBOV consensus genomes were assembled for each time
point and sample and then used to derive EBOV protein se-
quences. Alignment of these sequences produced a
consensus sequence covering the full length of the
GP gene. All the amino acids identified to be critical
for targeting by ZMAb were represented in each con-
sensus sequence (Fig. 5). This data suggested that
there was no selection of antibody escape mutants to
form the dominant amino acid sequence in a consen-
sus population at the dosing schedule used.
The application of ZMab, although not affecting the
consensus EBOV genome population, may have acted as
a selection pressure at the level of minor variants, e.g.
changes in sequence that did not achieve a 50% thresh-
old, and hence become consensus sequence. To investi-
gate this, the pattern of minor variants within the EBOV
genome at each time point was examined (Fig. 6). The
data suggested that there was no overall large increase in
minor variant frequency in any codon position and par-
ticularly at positions 1 and 2 that would have been indi-
cative of a non-synonymous substitution and emergence
of specific escape mutants to ZMab (Fig. 6).
Fig. 5 Consensus sequence in the portions of the EBOV genome corresponding to the ZMAb binding sites identified in GP. In red are amino
acids targeted by the antibody cocktail that forms ZMab
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Analysis of virus population genetics suggested the
antibody response was directed against the consensus
genome population
During infection, there are various evolutionary pres-
sures placed on the virus, including the innate immune
system early in infection transitioning to the adaptive
response and the production of neutralising antibodies
some 10–12 days post-infection. Longitudinal samples
were analysed to investigate EBOV population genetics
in UK2. Phylogenetic analysis of the consensus nucleo-
tide sequences of EBOV in UK2 at different sampling
points indicated a lack of divergence (Fig. 7). Day 12
Fig. 6 Minor variant frequencies at specified amino acid positions involved in binding the monoclonal antibodies that form ZMab in EBOV GP for
the different time points post infection, including recrudescence
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post admission was the most divergent sample, based on
an analysis of coding sequence, with the recrudescent
plasma and CSF samples being most similar to day 10/
day11, suggesting that potentially prior to day 12, EBOV
had migrated to the central nervous system, considered
an immune privileged site. Whilst there was no overall
major change in EBOV consensus sequence, variation in
the EBOV genome was investigated between each sam-
ple and whether potential nucleotide variation occurred
at the level of minor variants. Analysis of minor variants
showed that these were frequent on day 1, and then ap-
peared restricted on days 4 to 8 (Fig. 8). Several hypoth-
eses could account for this. First, was the lower
sequence read depths mapping to the EBOV genome,
providing noisier data, although the general trend in the
pattern of minor variants was similar at all days. To
investigate this possibility, 62% of the reads were ran-
domly removed from day 6 to make the read depth
equivalent to the day 11 and day 12 read depths. The
mapping depths were compared before and after the
subsampling. This indicated the random selection had
no bias and no change in the frequency of variants, sug-
gesting that the minor variants were real phenomena
(Fig. 9). Second, is that the immune therapy given (con-
valescent sera/monoclonal antibodies) restricted the viral
genotypes. However, as described, there was no evidence
of minor variants being selected in response to ZMab,
and anecdotal evidence suggested that the convalescent
sera used was not neutralising. Although this treatment
may have placed some selective pressure on the virus
through Fc mediated antiviral actions. Minor variants
appeared to increase in frequency on day 9 and become
Fig. 7 Phylogenetic analysis and comparison of EBOV sequence of the 1st, 2nd and 3rd codons and non-coding sequences in UK2 (from both
the first and recrudescent infections) with EBOV genome sequences from the West African (2013–2016) and earlier outbreaks back to 1976
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more common place by day 12. This corresponded with
the large decrease in viral load on these days compared
to peak viral load at day 6.
EBOV persistence may be due to a state of significantly
reduced rate of viral replication rather than defective
genomes
The presence of EBOV in sites described as immune pri-
vileged in both non-human primate models [36, 37] and
in survivors of the 2013–2016 West African outbreak
[13, 38] has been suggested as potentially containing res-
ervoirs of virus that can initiate new infections many
months after an individual has been declared free of
EBOV. As described herein and previously [16], UK2 de-
veloped EVD approximately 9 months after being dis-
charged from the first infection with EBOV. This
manifested in a severe acute meningo-encephalitic illness
with fever, severe headache and photophobia and bilat-
eral VI, left pupillary-sparing partial III, left upper motor
neuron VII and left VIII cranial nerve palsies and left-
sided cerebellar dysfunction. A markedly higher viral
load was present in CSF than plasma and MRI scanning
of the brain confirmed involvement of the leptomenin-
ges, brainstem, cranial nerves, cauda equina, conus
medullaris and left cerebellar hemisphere. This fluid sur-
rounds central nervous system sites described as im-
mune privileged. After the case report for the
recrudescent illness involving meningoencephalitis in
this patient was published [16], the presence of aber-
rantly synthesised EBOV genomes, termed defective
interfering (DI), was proposed as a potential mechanism
to maintain a persistent infection of EBOV [39]. In this
case, the DIs proposed, copy backs, are formed from the
5′ end of the genome, and outcompete the genome in
terms of replication. Thus, from the sequence data, a
greater number of sequence reads would be predicted to
map to the 5′ end versus the 3′ end of the genome if
this type of DI was present. Another form of DI, called a
deletion DI, is created through discontinuous RNA syn-
thesis. Alternatively, to DIs supressing or competing
with virus replication, the virus may have entered a state
of reduced or less efficient replication, in which case, the
rate of non-synonymous versus synonymous substitu-
tions would be lower than would predicted based on the
expected rate of genome evolution from studies that in-
clude transmission. This latter hypothesis is possible be-
cause phylogenetic analysis indicated that the major
evolutionary driving force in the initial infection was
non-synonymous changes, whereas between the initial
infection and recrudescence the predominant mutations
were synonymous (Fig. 7).
To investigate the presence of DIs, the viral sequen-
cing data from UK2 was analysed both for read depth at
the 3′ and 5′ ends and also fusion events using the Di-
tector algorithm to establish the frequency of discon-
tinuous fusion events, which would be characteristic of
deletion DIs [29]. Further, the same fusion event would
be predicted to be in multiple sequential samples if the
DI became established and was propagated during repli-
cation of viral RNA. The read depth analysis indicated
no enrichment of sequence reads mapping to the 5′ end
of the genome relative to the 3′ end suggesting that copy
back DIs had not become established in any of the sam-
ples (Fig. 10).
Fig. 8 Map of minor variants across the EBOV genome for each
sample (day 4 to day 12) and during recrudescence. A schematic of
the position of EBOV genes along the genome is shown on
the X-axis
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Analyses of the sequence data by Di-tector indicated a
diverse array of fusion events in many of the samples ei-
ther within or between negative (genome) and positive
(anti-genome) strands (Table 2). Mostly these were con-
fined to short deletions of the genome. DIs can be pack-
aged into virions and therefore spread during infection.
Several the same fusion events were present in multiple
days and also in the CSF and also increased with read
depth from sequential days in the blood samples
(Fig. 11). This suggested that potentially the same DI
was being propagated. However, the reads mapping to
the fusion events were never in the majority and infre-
quent compared to the total number of reads mapping
to the EBOV genome, including in the CSF.
As discussed, alternatively, the virus may have entered
a state of low level replication, proposed by Young et al.
for other viruses [40]. Here, genome variants may be se-
lected for in which virus replication is suppressed and
may therefore evade antiviral activity and a cellular
response. Previously, comparison of non-synonymous
changes between EBOV in the plasma and CSF re-
vealed only two non-coding changes, present and
identical in both samples, compared with the original
sequence from plasma (NCBI accession numbers
KU052669 and KU052670) [16]. Herein, EBOV gen-
ome sequence from these samples was also compared
to the samples taken at different days from the ori-
ginal infection. Given that the nucleotide substitution
frequency, as calculated from data from the West Af-
rican outbreak [4], was in the order of 1.42 × 10−3
substitutions per site per year, we would expect ap-
proximately 22 nucleotide substitutions over a 9- to
10-month period.
The ratio of non-synonymous substitutions (dN) and
synonymous substitutions (dS) were compared between
day 1 and day 12 showing a substitution rate of 0.4323
for the NP gene, 0.6717 for the VP35 gene, 0.0961 for
the GP gene, and 0.3545 for the L gene, with VP40,
VP30 and VP24 showing no evidence of nucleotide sub-
stitution. This shows potentially differential selection
pressure acting along the EBOV genome during infec-
tion. The analysis was similarly performed between day
9 (when we postulate EBOV became established in a
state of less active replication) and the samples taken in
2015 using yn00 in the paml package. Unlike the small
rate of substitution seen between days 1 and 12, com-
parison between day 9 and recrudescent infection several
months in 2015 later showed no significant genomic
changes.
Discussion
Whilst both the host response [6, 7, 30] and the pres-
ence of co-infections [8] may contribute to the outcome
in EVD, the overwhelming factor is viral load, with high
viral loads (Ct < 18.1) being associated with a fatal out-
come [4, 5]. The analysis of both viral load and the host
response through sequencing blood samples from UK2
and comparison to equivalent matched patients from
Guinea revealed the severity of the infection in UK2
(Table 1). In our experience, West African patients with
Fig. 9 Distribution of sequence reads mapping to the EBOV genome before and after randomised sub sampling. Day 6 was chosen as a comparison
point. A schematic of the position of EBOV genes along the genome is shown on the X-axis
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these viral loads invariably had a fatal outcome. Simi-
larly, in West African patients upon testing at the Ebola
Treatment Centre, in those patients who succumbed to
the disease, there was a greater upregulation of inter-
feron signalling and acute phase responses, compared to
patients who went on to survive infection [6]. Particu-
larly notable was the strong upregulation of gene tran-
scripts associated with significant liver pathology. Cell
subtype prediction using mRNA expression patterns in
the blood indicated that natural killer (NK) cell popula-
tions were greater in patients who went on to survive in-
fection versus patients who went on to have a fatal
outcome [6]. Fatal EVD in these patients was also char-
acterised by strong T-cell activation [34]. The data indi-
cated that the abundance of transcripts associated with
severe and fatal infection in West African patients [6] at
the early time points in UK2, e.g. days 5 and 6, was
greater (Figs. 2 and 3), suggesting that UK2 would have
been predicted to have a fatal outcome. This frames the
question of how UK2 survived.
UK2 was administered a monoclonal antibody cock-
tail, ZMab, on two occasions. Data from experiments
in non-human primate models of EVD suggested that
such therapeutics enhanced the chance of survival.
For example, the monoclonal antibody cocktail MB-
003, provided 50–100% survival in rhesus monkeys
when administered within 24–72 h after EBOV inocu-
lation [41]. A different cocktail of antibodies called
ZMAb (Public Health Agency of Canada) resulted in
100% survival when administered to cynomolgus ma-
caques 24 h after exposure to EBOV [42], and was
used to treat a repatriated healthcare worker [43].
During the 2013–2016 EBOV outbreak in West Af-
rica, a different formulation called ZMapp was also
used. This had also previously been shown to be ef-
fective in the treatment of nonhuman primates with
Fig. 10 Read depth analysis of samples sequenced. A schematic of the position of EBOV genes along the genome is shown on the X-axis for the
mapping rate, and the lower two analyses focus on the reads mapping to the 3′ and 5′ ends of the genome. Mapping rates were shown before
and after filtration, i.e. the MAPQ > 10 and PCR duplicates were removed
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EVD after 5 days post experimental infection [44]. Al-
though a randomised control trial in humans using a
combination of ZMapp plus the current standard of
care versus the current standard of care alone showed
some benefit, the study did not reach the prespecified
statistical threshold for efficacy [11]. In certain exam-
ples, EBOV escape mutants have been identified when
antibody-based therapy has been used to inhibit/re-
duce EBOV infection in non-human primate models
of infection [45]. The RNAseq data from UK2 re-
vealed a decrease in reads mapping to the viral gen-
ome after the application of the monoclonal antibody
cocktail ZMab. This was perhaps a more accurate in-
dication of the amount of virus than the RT-qPCR
analysis. Although UK2 was effectively a N of one, we
hypothesise that given both viral and cellular markers
were predictive of a fatal outcome, the application of
ZMab was responsible for the dramatic lowering of
viral load, and the change in the patient from a pre-
dicted fatal outcome to a survival pathway. This was
perhaps evidenced by the DCQ analysis suggesting a
greater abundance of natural killer cells as the time
increased post-presentation and viral load decreased
(Fig. 4). DCQ analysis of samples from West African
survivors at the acute phase of infection suggested a
greater abundance of NK cells compared to equivalent
patients who went on to have a fatal infection [6].
This was confirmed in further experiments using flow
cytometry [46], where CD56 negative NK cells were
associated with a survivor outcome [46]. The DCQ
analysis of the samples from UK2 predicted an in-
crease in CD56- NK cells (Fig. 4).
Given the scale of the outbreak and attention, sev-
eral aspects of EVD came to the forefront including
the potential for recrudescence after the initial infec-
tion and persistence of the virus in immune privileged
sites [13, 14, 16]. Similar to patients from West Africa
and other repatriated health care workers [14], UK2
suffered a recrudescent infection 10 months after their
initial infection—despite there being no evidence of
EBOV in the blood after the first infection. Several
mechanisms may account for the recrudescence, in-
cluding a ‘latent state’ and the possible role of DIs as
way of modulating virus replication [39] to levels
below the limit of detection. Certainly, this hypothesis
is not without merit, as defective measles virus ge-
nomes have been identified in the brain cells of pa-
tients with subacute sclerosing panencephalitis (SSPE)
[47]. If this were the case with UK2, we would hy-
pothesise that DIs would compete for viral proteins
involved in RNA synthesis and other processes and
maintain low levels of viral genomes. Recrudescence
would then be explained through the resurgence of
the viral genome—similar to predator/prey relation-
ships. Analysis of the RNA sequencing data from both
the initial infection and recrudescence in UK2 indi-
cated that at no point did the DIs become the
majority population. Overall, we conclude that DIs
(assuming they are not artefacts of the sequencing
protocols) may have been present at levels where they
did not outcompete genomic replication and therefore
did not significantly impact virus lifecycle.
Rather, based on the lack of viral sequence diversity/evolu-
tion between the initial infection and relapse, we favour a
model of the virus entering a state of reduced virus replica-
tion, as suggested by the phylogenetic analysis based on cod-
ing versus non-coding changes (Fig. 2). Recently, models of
persistence in RNA viruses that cause acute infections have
Table 2 Frequency of defective viral genomes detections
Total DI reads 5′ DVGs 3′ DVGs DVGs with deletion DVGs with insertion
Day 1 83 8 (9.4%) 1 (1.2%) 28 (33.73%) 46 (55.42%)
Day 4 4096 3163 (77.22%) 815 (19.90%) 24 (0.59%) 94 (2.29%)
Day 5 68,219 55,389 (81.19%) 10,926 (16.02%) 447 (0.66%) 1457 (2.14%)
Day 6 109,650 96,162 (87.70%) 11,518 (10.50%) 498 (0.45%) 1472 (1.34%)
Day 7 90,244 71,070 (78.75%) 17,882 (19.82%) 433 (0.48%) 859 (0.95%)
Day 8 76,582 59,710 (77.97%) 16,004 (20.90%) 325 (0.42%) 543 (0.71%)
Day 9 13,202 10,145 (76.84%) 2904 (22.00%) 55 (0.42%) 98 (0.74%)
Day 10 7449 5346 (71.77%) 2074 (27.84%) 17 (0.23%) 12 (0.16%)
Day 11 2179 1678 (77.01%) 471 (21.62%) 14 (0.64%) 16 (0.73%)
Day 12 2914 2125 (72.92%) 762 (26.15%) 10 (0.34%) 17 (0.58%)
Plasma-081015 16 4 (25.00%) 11 (68.75%) 0 (0.00%) 1 (6.25%)
CSF-071015 437 154 (35.24%) 197 (45.08%) 22 (5.03%) 64 (14.65%)
CSF-081015 463 137 (29.59%) 215 (46.44%) 33 (7.13%) 78 (16.85%)
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been proposed where single amino acid substitutions in viral
proteins can result in aberrant RNA replication [40]. Restor-
ation of the wild-type or alternative functional amino acid re-
sults in lytic infection [40]. To account for the recrudescent
infection in UK2, we hypothesise that whilst a robust adap-
tive immune response cleared the consensus EBOV genome
population in the original infection, minor variant virus pop-
ulations were harboured in immune privileged sites.
Fig. 11 In left scatter-plot, the breakpoint site (BP) and re-initiation site (RI) positions are respectively used for “x” and “y” axis, and the closer the
dot is to the diagonal of the scatter plot, the smaller the distance between BP and RI. In the right chord diagram, sequence starts at the viral
genome extremity, jumps from BP to RI and terminates from RI to genome extremity again. Colour and dot/line size change according to DI
genome type and frequency
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These minor variants may have been deficient in repli-
cation and protected from the immune response. This
would lead to persistence of the virus. In which case, the
restoration of efficient replication through mutation and
random chance led to a second EBOV infection and po-
tentially the requirement for the generation of further
neutralising antibodies. Analysis of the virus population
genetics in the initial infected revealed a narrowing of
the minor variants from day 4 to day 10. To account for
this observation, we postulated that although the im-
mune system will be directed against the whole virus
population, the dominant immune response would have
been against the consensus phenotype/genotype of the
virus, potentially eliminating the consensus genotype vi-
ruses at an accelerated rate compared to viruses carrying
minor variants. Analysis of the minor variant frequency
in the samples taken during recrudescence indicated
fewer variants compared to the original infection.
Conclusions
This sequencing analysis provided a longitudinal natural
history of infection and the corresponding host response
in a patient with EVD. Together with the supportive care,
the use of the medical countermeasure ZMab was likely to
have changed UK2’s pathway from a fatal outcome to sur-
vival. The study thus provides direct molecular evidence
to support the supposition by one of the authors (and at-
tending physician for UK2) [17] that despite an initial un-
favourable prognosis (i.e. death), disease management and
treatment in extreme cases of EVD are worth pursuing.
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